Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...